A multi-centre 3-year follow-up study to assess the viral activity in patients who failed to achieve sustained virologic response in Novartis-sponsored alisporivir studies for chronic hepatitis C patients
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Alisporivir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- Sponsors Novartis Pharma A.G.
- 13 Dec 2017 Status changed from completed to discontinued.
- 19 Dec 2012 Integrated Clinical Trials Registry - India record.
- 19 Dec 2012 New trial record